NCT01835717 · COMPLETED
Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population
This is an observational study, not a drug trial. Nothing is being given to participants. Researchers give cognitively healthy adults memory and thinking tests, plus a questionnaire and a DNA blood sample. They want to see whether test scores differ by lifestyle, background, and genes. Phase is not specified because there is no treatment being tested.
Eligibility criteria
Inclusion Criteria: 1. Men and women, aged between 45 and 75 years 2. Spanish and/or Catalan speakers 3. Agreement with the study procedures and tests: 1. Clinical Interview and questionnaires associated to risk factors 2. Cognitive tests 3. Blood sample extraction for DNA analysis 4. Close relative involvement for functional evaluation of the volunteer 5. Signature of informed consent Exclusion Criteria: 1. Cognitive impairment: MMSE \<26, o MIS \<6, or orientation subtest of the Barcelona Test II \<68, o category fluency (animals) \<12 2. Functional status impairment: CDR > 0 3. Severe auditory and/or visual impairment 4. Neurodevelopmental and/or psychomotor disorder 5. Significant diseases that could currently interfere with cognition: renal failure on hemodialysis, liver cirrhosis, chronic lung disease with oxygen therapy, solid organ transplantation, fibromyalgia, active cancer in treatment or any other disease the investigator considers could affect the participant cognition 6. Major psychiatric disorders (DSM-IV-TR) or diseases that could affect cognitive abilities: major depression, bipolar disorder, schizophrenia and dementia. 7. Neurological disorders: Parkinson's disease, stroke, epilepsy and treatment with frequent seizures (> 1/month) in the past year, multiple sclerosis or other serious neurological disease. 8. Brain injury interfering with cognition: history of head trauma with parenchymal lesion or extraaxial macroscopic large vessel ischemic stroke or hemorrhagic stroke, brain surgery, brain tumors and other causes that can generate acquired brain damage (cerebral chemotherapy or radiotherapy) 9. Family history of Alzheimer's disease with autosomal dominant (3 affected in two different generations) and early onset age (\<60 years).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2021-06-10